NCT04062253

Brief Summary

Data on the prevalence of hepatitis C virus (HCV) for other vulnerable groups in Madrid, such as homeless persons and migrants, are scarce, and it is now necessary to implement intervention and elimination plans. Vulnerable groups have poor access to healthcare and are therefore not systematically screened for HCV. On the occasions they are shown to be positive, subsequent follow-up in the health system and the possibility of cure are poor. The use of a mobile unit to approach vulnerable populations is essential for better characterization of risk behaviors and of the magnitude of HCV. The integration of healthcare personnel in mobile units enables counseling on prevention and intervention when needed. Primary objective Evaluate the impact of the HCV care cascade on vulnerable populations who gather at hot spots in Madrid (shantytowns, homeless shelters and places were street prostitution is practiced) by means of a multilevel outreach project. SURVEILLANCE: Active screening for HCV among vulnerable individuals in populations with a high prevalence of HCV will be carried out in hot spots in Madrid, namely, Cañada Real shanty town, mobile harm reduction units, institutions providing social assistance, public areas, homeless shelters and places where street prostitution is practiced. An agreement with the Madrid Council (MCC) is under way to provide social centers for HCV screening. A mobile unit will approach the hot spots following a predefined schedule. The mobile unit consists of a van adapted for the project and a car. HCV screening of vulnerable individuals will be performed by a nurse and an educator hired specifically for that purpose. Active HCV screening and prevention in vulnerable individuals should be a priority and a responsibility shared by both the MCC and the SERMAS (Servicio Madridleño de Salud). The investigators plan to establish an agreement with public health authorities to give continuity to this project and to carry out proactive HCV screening through integration with various centers and networks dependent on the MCC and SERMAS. The project will establish the foundations of integrated cooperation between an HCV clinic in a hospital setting and harm reduction units and other resources and networks dependent on the institutions mentioned above. As has been observed with other interventions, the functional objective of this project is to provide continuity of care from the institutions. Study Duration (in months) 12 months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,001

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2019

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 10, 2019

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 20, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2020

Completed
Last Updated

February 9, 2021

Status Verified

February 1, 2021

Enrollment Period

1.1 years

First QC Date

May 10, 2019

Last Update Submit

February 8, 2021

Conditions

Keywords

HIVHCVPWID (Persons who inject drugs)ScreeningDiagnosisLinkage to careTreatment

Outcome Measures

Primary Outcomes (2)

  • Percentage of Participants Who have a positive RNA HCV test

    Percentage of those participants screened for HCV, Who hace a positive RNA HCV test using a Genexpret test onsite.

    1 year

  • Percentage of Participants Who have a positive HIV rapid test

    Percentage of those participants screened for HIV, Who hace a positive test

    1 year

Secondary Outcomes (1)

  • Percentage of Participants Who have an active HCV infection and start HCV therapy.

    1 year

Study Arms (2)

HCV or HIV negative

Individuals who test negative for HCV or HIV are given information regarding ways of transmission.

Diagnostic Test: HCV rapid test

HCV and HIV positive

Individuals with a positive test for HCV o HIV are offered delivery or accompaniment to specialist health care.

Diagnostic Test: HCV rapid test

Interventions

HCV rapid testDIAGNOSTIC_TEST

Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.

Also known as: HIV rapid test, Xpert HCV viral load, Xpert HIV viral load, Linkage to care
HCV and HIV positiveHCV or HIV negative

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Persons who inject drugs (PWID), homeless people, migrants and sex workers are vulnerable populations that have a high prevalence of active hepatitis C virus (HCV) infection. According to local data, the prevalence of HCV in drug users ranges from 20% to 60%, depending on whether they inject drugs or not. Data on the HCV prevalence for the other vulnerable groups (homeless, migrants…) in Madrid is scarce and necessary to implement intervention and elimination plans.

You may qualify if:

  • Vulnerable populations who include one or more of the following:
  • Persons who inject drugs,
  • Homeless,
  • Migrants
  • Sex workers

You may not qualify if:

  • Not signing inform consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unidad Movil de Cribado

Madrid, Spain

Location

Related Links

MeSH Terms

Conditions

Hepatitis CHIV InfectionsHepatitis BDisease

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepatitis, Viral, HumanVirus DiseasesFlaviviridae InfectionsRNA Virus InfectionsHepatitisLiver DiseasesDigestive System DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesHepadnaviridae InfectionsDNA Virus InfectionsPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 10, 2019

First Posted

August 20, 2019

Study Start

February 15, 2019

Primary Completion

March 15, 2020

Study Completion

March 15, 2020

Last Updated

February 9, 2021

Record last verified: 2021-02

Locations